Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GlaxoSmithKline

Glaxo (GSK) and Vir are looking to get authorization for the intramuscular administration of their COVID-19 drug candidate, sotrovimab, which is currently authorized for intravenous administration.

Glaxo (GSK), Vir Seek EUA for Intramuscular Sotrovimab in US

Shares of Vir Biotechnology Inc. VIR, -1.60% were up 1.0% in trading on Thursday after the company and GlaxoSmithKline GSK, -0.01% formally asked the Food and Drug Administration to update the authorization for their COVID-19 treatment to include intramuscular administration. GSK's stock was up 0.1% after the news was announced.

Vir, GSK ask FDA to update EUA for their monoclonal antibody to include intramuscular administration

– New commitment from the Bill & Melinda Gates Foundation supports the development of Vir's novel “vaccinal antibody” technology as another important step in the fight to address global infectious diseases –

Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria

– If authorized, would provide the option for intramuscular administration of sotrovimab, in addition to currently authorized intravenous administration –

GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19

Vir Biotechnology, Inc. (VIR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Vir Biotechnology, Inc. (VIR) Soars 15.1%: Is Further Upside Left in the Stock?

The U.S. government enters into an agreement with Glaxo (GSK) and Vir Biotechnology (VIR) to procure an additional 600,000 doses of sotrovimab for early treatment of COVID-19.

Glaxo (GSK) & Vir to Supply More COVID Antibody Doses in US

After losing some value lately, a hammer chart pattern has been formed for Vir Biotechnology, Inc. (VIR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Vir Biotechnology, Inc. (VIR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

The U.S. has agreed to buy 600,000 more doses of GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) COVID-19 antibody therapy for an undisclosed sum. The companies would supply the additional doses of sotrovimab to the U.S. in Q1 of 2022, taking the tally of doses secured by nations worldwide to roughly 1.7 million.

US To Purchase 600K Additional Doses of GSK-Vir's COVID-19 Antibody Therapy

GlaxoSmithKline GSK, -0.60% GSK, +0.83% and partner Vir Biotechnology VIR, +1.96% said Tuesday that the U.S. government will buy 600,000 doses of sotrovimab, an investigational monoclonal antibody for early COVID-19 treatment. The extra doses will be delivered in the first quarter of 2022 to the U.S., which has an option to purchase more in the second quarter.

GlaxoSmithKline, Vir shares up as U.S. orders more doses of COVID treatment sotrovimab

The new deal brings to 1 million the total number of doses of the therapy that the U.S. government has purchased, according to GlaxoSmithKline.

Glaxo and Vir Sell 600,000 Covid Antibody Doses to U.S.

GlaxoSmithKline GSK, +2.26% GSK, +1.24% and partner Vir Biotechnology VIR, -0.62% said Tuesday that the U.S. government will buy 600,000 doses of sotrovimab, an investigational monoclonal antibody for early COVID-19 treatment. The extra doses will be delivered in the first quarter of 2022 to the U.S., which has an option to purchase more in the second quarter.

GlaxoSmithKline to ship 600,000 more doses of COVID treatment sotrovimab to U.S.

– 600,000 additional doses to be supplied to the US government for distribution in Q1 2022,  enabling further access to sotrovimab nationwide –

GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19

Amgen

Beam Therapeutics

These stocks are poised for a strong year.

My 3 Top Biotech Stock Picks for 2022

Novavax

Pfizer

These three COVID-19 stocks could rake in a tremendous amount of cash this year.

3 COVID Stocks That Will Make Billions in 2022

GlaxoSmithKline PLC GSK, -0.18% announced Thursday an agreement to supply the Government of Canada with 20,000 doses of Sotrovimab, the COVID-19 monoclonal antibody therapy the company developed with Vir Biotechnology Inc. VIR, +0.20% . The agreement follows Canada's initial order of 10,000 doses of Sotrovimab announced in October, which included options for additional purchases.

GlaxoSmithKline, Vir increases supply of COVID-19 antibody therapy to Canada to 20,000 doses

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 1:30 p.m. ET.

Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 3% in the most recent trading session. This is why it happened.

Vir Biotechnology Stock (VIR): Why The Price Increased

–  Growing body of evidence validates Vir's approach of targeting a highly conserved region of the spike protein –

Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement

AstraZeneca

Regeneron Pharmaceuticals

We take a look at the data reported so far on antibody treatments by Regeneron (REGN), AstraZeneca (AZN) and Vir (VIR) amid the Omicron variant scare. The results have been mixed mostly.

Omicron Variant Puts COVID-19 Antibody Treatments in Focus

The European Commission (EC) has granted marketing authorization to GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc's (NASDAQ: VIR) Xevudy (sotrovimab) for the early treatment of COVID-19.  Sotrovimab is now approved in the European Union (EU) for adults and adolescents (aged 12 years & above and weighing at least 40kg) with COVID-19 who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19.

Glaxo-Vir Biotech's Antibody Approved In Europe For Early Treatment Of COVID-19

LONDON and SAN FRANCISCO, Dec. 17, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Commission (EC) has granted marketing authorization to Xevudy (sotrovimab) for the early treatment of COVID-19. Sotrovimab is now approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40kg) with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19

The immunology specialist says it can help combat omicron.

Why Vir Biotechnology Stock Surged Today

Vir Biotechnology Inc (NASDAQ: VIR) announced new preclinical data, published to the preprint server  bioRxiv , demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529).  A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals.

Why Are Vir Biotech Shares Gaining Today?

– Data demonstrate sotrovimab, developed by Vir in conjunction with GlaxoSmithKline, continues to retain in vitro neutralizing activity against all tested variants of concern, including Omicron –

Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies

– Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV –

Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection

News for Vir Biotechnology Stock (VIR)